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Abstract Mass screening for osteoporosis using DXA
measurements at the spine and hip is presently not rec-
ommended by health authorities. Instead, risk factor
questionnaires and peripheral bone measurements may
facilitate the selection of women eligible for axial bone
densitometry. The aim of this study was to validate a
case ﬁnding strategy for postmenopausal women who
would beneﬁt most from subsequent DXA measurement
by using phalangeal radiographic absorptiometry (RA)
alone or in combination with risk factors in a general
practice setting. The sensitivity and speciﬁcity of this
strategy in detecting osteoporosis (T-score £ 2.5 SD at
the spine and/or the hip) were compared with those of
the current reimbursement criteria for DXA measure-
ments in Switzerland. Four hundred and twenty-three
postmenopausal women with one or more risk factors
for osteoporosis were recruited by 90 primary care
physicians who also performed the phalangeal RA
measurements. All women underwent subsequent DXA
measurement of the spine and the hip at the Osteopo-
rosis Policlinic of the University Hospital of Berne. They
were allocated to one of two groups depending on
whether they matched with the Swiss reimbursement
conditions for DXA measurement or not. Logistic
regression models were used to predict the likelihood of
osteoporosis versus ‘‘no osteoporosis’’ and to derive
ROC curves for the various strategies. Diﬀerences in the
areas under the ROC curves (AUC) were tested for
signiﬁcance. In women lacking reimbursement criteria,
RA achieved a signiﬁcantly larger AUC (0.81; 95% CI
0.72–0.89) than the risk factors associated with patients’
age, height and weight (0.71; 95% C.I. 0.62–0.80).
Furthermore, in this study, RA provided a better sen-
sitivity and speciﬁcity in identifying women with
underlying osteoporosis than the currently accepted
criteria for reimbursement of DXA measurement. In the
Swiss environment, RA is a valid case ﬁnding tool for
patients with risk factors for osteoporosis, especially for
those who do not qualify for DXA reimbursement.
Keywords Case ﬁnding Æ DXA Æ General practice Æ
Postmenopausal osteoporosis Æ Radiographic
absorptiometry Æ Risk factors
Introduction
Bone mineral density (BMD) measurement at the hip
and lumbar spine using dual-energy X-ray absorptiom-
etry (DXA) is widely accepted as the gold standard in
the diagnosis of osteoporosis and as a basis for decision
making and monitoring of osteoporosis treatment [1, 2,
3]. However, the current guidelines do not recommend
BMD measurement with axial DXA as a mass screening
tool [3]. In Switzerland as in other European countries,
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DXA is covered by basic health insurance in a restricted
number of clinical situations (Table 1).
Although hip fracture prediction with BMD mea-
surement alone is at least as good as blood pressure
readings to predict stroke [4], there are no validated
mass screening strategies based on BMD measurement
with axial DXA available to date. On the other hand,
modern treatment options of osteoporosis targeted at
reducing fracture risk have been adequately documented
only in patients with low BMD at the spine and/or hip.
Therefore, various case ﬁnding strategies using individ-
ual risk factors or risk questionnaires have been pro-
posed to select women for bone densitometry [5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15]. Treatment would be considered
in individuals subsequently shown to have low BMD at
the spine and/or hip and who thereby have a high
fracture risk [16, 17].
Another approach to facilitate the selection of wo-
men eligible for bone densitometry was the develop-
ment and validation of osteoporosis screening devices,
based on bone measurements at peripheral sites of the
skeleton. Among these techniques, phalangeal ultra-
sound [18], computed digital absorptiometry [19, 20]
and radiographic absorptiometry (RA) [21, 22, 23, 24,
25, 26, 27, 28] have documented reasonable sensitivity
and speciﬁcity, which were, however, not suﬃciently
good to replace DXA for the diagnosis of osteoporosis.
Recently, we addressed the question of whether and
how well radiographic absorptiometry of the phalanges
predicted osteoporosis at the spine or hip (as diagnosed
by DXA) and whether a two-step diagnostic strategy
(using RA as the ﬁrst line to identify patients with low
bone mass and DXA as the second line to assess the
diagnosis of osteoporosis and take the treatment deci-
sion) was cost-eﬀective in postmenopausal women [25].
However, although the latter was the case, that study
did not assess the value of risk factors taken alone or in
combination with RA to increase the speciﬁcity and
sensitivity in detecting women with osteoporosis at the
spine and/or the hip as deﬁned by the WHO (T-score
£ 2.5 SD) [3].
The aim of this study was to validate a case ﬁnding
strategy for postmenopausal women who would beneﬁt
most from subsequent DXA measurement to diagnose
osteoporosis. Therefore, the speciﬁcity and sensitivity of
RA measurements, alone or in combination with se-
lected risk factors, in predicting low bone mass were
estimated in a general practice setting in Switzerland.
Furthermore, the eﬃciency of this case-ﬁnding strategy
was compared to today’s medical practice based on the
current Swiss reimbursement criteria for DXA mea-
surements.
Materials and methods
Participants
Four hundred and twenty-three postmenopausal women
were recruited by 90 participating primary care physi-
cians in the cantons of Berne and Vaud in Switzerland,
listed in the Appendix. Women were eligible for the
study if they were postmenopausal, older than 45 years
of age and presented one or more risk factors for oste-
oporosis [history of hypogonadism, gastrointestinal
disease (malabsorption, Crohn’s disease or hemorrhagic
colitis), anamnestic or current long-term treatment with
glucocorticosteroids (>3 months, >7.5 mg equivalent
of prednisone per day), history of hysterectomy or
ovariectomy, low dietary calcium intake, positive family
history of osteoporosis, past or current nicotine abuse
(>10 cigarettes a day), substitution with thyroid hor-
mones and/or potential manifestations of osteoporosis
(history of fracture following a low velocity trauma or of
height loss ‡3.5 cm)].
Methods
The individual risk of a patient was assessed by the local
primary care physician using a standardized question-
naire with the above-mentioned risk factors. If one or
more risk factors were present, age, height and weight
were recorded, and a phalangeal X-ray of the non-
dominant hand (two exposures on the same ﬁlm) was
performed at the physician’s oﬃce. This X-ray was sent
by mail to the Osteoporosis Policlinic of the University
Hospital of Berne for digital computerization. Subse-
quently, all participating women were invited by the
Osteoporosis Policlinic, in agreement with the partici-
pating physician, to undergo DXA measurement.
Dual-energy X-ray absorptiometry (DXA)
Bone densitometry was performed at the lumbar spine
(LS, second to fourth lumbar vertebra) and at the fem-
oral neck (FN) using a Hologic QDR 1000 densitometer
(Hologic Inc., Bedford, Mass.). Bone mineral density
(BMD) was expressed as g/cm2 of hydroxyapatite and T-
scores (SD from peak bone mass). T-scores were based
on a quadratic regression calculated from a reference
population of 318 normal Caucasian women (20–
80 years, body mass index 18–31 kg/m2) living in the
area of Berne. Peak bone mass (mean value ± SD) was
1.044±0.117 at the lumbar spine (L2–L4) and
Table 1 Reimbursed DXA indications in Switzerland
Clinically evident osteoporosis*
Fracture following a low velocity trauma
Long-term treatment with glucocorticosteroids
Hypogonadism
Gastrointestinal diseases (malabsorption,
Crohn’s disease, hemorrhagic colitis)
Primary hyperparathyroidism
Osteogenesis imperfecta
*E.g., clinically documented height loss
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0.827±0.098 at the femoral neck. Subjects with a T-
score at the lumbar spine and/or femoral neck below or
equal to –2.5 SD (0.752 g/cm2 and 0.582 g/cm2, respec-
tively) were deﬁned as osteoporotic, in accordance with
the WHO deﬁnition [3]. Daily quality control was per-
formed using the anthropometric spine phantom sup-
plied by the manufacturer: overall precision error was
0.3% in vitro, and in vivo mean precision error was
1.0% in our hands.
Radiographic absorptiometry of the phalanges (RA)
The technique has been described in detail earlier [21, 26,
28]. Brieﬂy, ﬁngers of the non-dominant hand and an
aluminum wedge were radiographed with the available
radiographic equipment at the site, using a non-screened
pre-packed sealed industrial ﬁlm by Kodak. Two expo-
sures (50 kV, 300 mAs and 60 kV, 150 mAs; focus dis-
tance 1 m) were performed on the same ﬁlm, which was
developed at the primary care physician’s oﬃce and then
sent by regular mail to the Osteoporosis Policlinic of the
University Hospital of Berne, where it was digitized for
subsequent computer analysis using a high resolution
video camera (OsteoGram Processing System, Comp-
uMed Inc, Calif.). The regions of interest were deﬁned
such as to encompass the wedge as well as the middle
phalanges of the index, third and fourth ﬁngers. Inter-
ference by soft tissues was cancelled out mathematically
by subtracting soft tissue absorption on either side of the
bone for each scan line. The volumic density of com-
posite bone was calculated in arbitrary units (AU) for
each phalange and the results averaged. The results were
considered as not valid if the diﬀerence between the two
exposures exceeded 2%. The skin dose on the hand was
estimated to amount to 0.1 mSv [29] and the eﬀective
dose to 1 lSv, i.e., similar to the radiation dose from
DXA [30]. The precision error was in our hands is 1–
1.5%.
Statistical analysis
Participants were separated into two groups for the
analysis: group 1 consisted of women who met one or
more of the current reimbursement criteria for DXA in
Switzerland shown in Table 1 and group 2 consisted of
all other women. In each group, three diagnostic cate-
gories were created, based on the T-scores at the lumbar
spine and femoral neck measured by DXA: ‘‘normal’’
(T-score >–1 SD at LS and FN), ‘‘osteopenia’’
(T-score £ 1 SD at LS and/or FN but >–2.5 SD at
either site) and ‘‘osteoporosis’’ (T-score £ 2.5 SD at LS
and/or FN). In both groups signiﬁcance tests were done
to assess diﬀerences in patient characteristics and fre-
quency of risk factors between the three categories. Chi-
square test statistics for categorical variables and
ANOVA F -values for continuous variables were cal-
culated. RA-test characteristics were analyzed after
pooling of the categories ‘‘normal’’ and ‘‘osteopenia’’
into a ‘‘no osteoporosis’’ category.
Logistic regression models were used to predict the
likelihood of osteoporosis (versus ‘‘no osteoporosis’’)
and to derive receiver operating characteristics (ROC)
curves that summarized test speciﬁcity and sensitivity at
diﬀerent cut-oﬀ values. Five diﬀerent logistic regression
models were deﬁned, including the following variables:
age, height and weight (model 1), age, height and weight
combined with all risk factors (model 2), RA measure-
ment alone (model 3), RA measurement combined with
age, height and weight (model 4) and RA measurement
combined with age, height and weight and all risk fac-
tors (model 5). In these regressions age was centered at
65 years, weight at 67 kg, height at 160 cm and RA
measurement at 91 AU. Diﬀerences in the areas under
the ROC curves were tested for signiﬁcance. In addition,
the sensitivity and speciﬁcity of RA were calculated for
selected RA cut-oﬀ values (<100, <95, <90, <87.5,
<85 AU) in the group of women without a reimbursed
DXA indication (group 2), using ‘‘osteoporosis’’ as the
disease deﬁnition. All statistical analyses were done with
Stata Statistical Software, version 8.2.
This study was a protocol extension of an earlier pilot
study approved by the Ethical Review Committee of the
University Hospital of Berne, and written informed
consent was obtained from all participants.
Results
X-rays of the phalanges and risk questionnaires were
obtained from 423 participants recruited by 90 general
practitioners. Forty-one participants were excluded
from the analysis: 23 had X-rays that could not be
evaluated due to either technical artifacts or to major
deformities of the interphalangeal joints. An additional
nine participants had non-reliable DXA results [physical
inability to lie in a supine position (n=1), bilateral total
hip endoprosthesis (n=3), metal implants in the lumbar
spine (n =2) and a discrepancy between T-scores of the
lumbar spine and femoral neck of more than 3 SD
(n =3)]; eight participants were younger than 45 years
and from one participant, clinical data were not avail-
able. The data sets from 382 participants aged 45 to
91 years (mean 66.9±10.1 years) with complete infor-
mation on risk factors, RA value and DXA measure-
ment at LS and FN were analyzed (Fig. 1).
Participants’ characteristics
Group 1 consisted of 190 women who met at least one
eligibility criteria for DXA reimbursement. Nineteen
percent of the patients in this group had normal BMD
values, 42% had osteopenia and 39% had osteoporosis
either at the lumbar spine and/or the femoral neck.
These three categories diﬀered for age (P =0.0002),
weight, BMI and RA values (P <0.0001 for all three),
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but not for height ( P =0.119), patients with osteopo-
rosis being signiﬁcantly older, with a lower body weight,
BMI and RA value than normal and osteopenic par-
ticipants (Table 2).
Group 2 consisted of 192 women who had no eligi-
bility criteria for DXA reimbursement. Twenty-six per-
cent of the patients in this group had normal BMD
values, 56% had osteopenia and 18% had osteoporosis.
These three categories diﬀered for age (P =0.0065),
height (P=0.023), weight (P=0.001), BMI (P=0.039)
and RA values (P <0.0001), patients without osteo-
porosis being signiﬁcantly younger, taller, heavier
and having higher RA values than those with osteo-
porosis.
Areas under the ROC curves (AUC)
In both groups, the combination of the parameters age,
height and weight resulted in an AUC of 0.7 (95% C.I.
0.62–0.79). The inclusion of additional risk factors did
not signiﬁcantly improve the AUC, in either group.
However, RA, either alone (group 2) or together with
age, height and weight (group 1) allowed for a signiﬁcant
improvement of the AUC, which was increased beyond
0.8. The inclusion of additional risk factors did not allow
for a signiﬁcantly larger AUC in patients without a
reimbursed DXA indication (Fig. 2, Table 3).
Sensitivity and speciﬁcity of the RA measurement
In participants without a reimbursed DXA indication,
the RA cut-oﬀ value of 95 arbitrary units (AU) or below
provided a sensitivity of 91.4% and a speciﬁcity of
45.9% to detect osteoporosis at the spine or the hip
(Table 4). In other words, more than 90% of the
patients with underlying osteoporosis would be identi-
ﬁed if the RA cut-oﬀ value were set at 95 AU. In con-
trast, the presence of a reimbursed DXA indication in
this patient population with prevalent risk factors for
osteoporosis had a sensitivity of 67.9% and a speciﬁcity
of 57.5% to predict osteoporosis (Table 5). In other
words, based on current DXA reimbursement criteria,
less than 70% of the patients with underlying osteopo-
rosis are correctly identiﬁed, while almost 60% of those
not having osteoporosis are identiﬁed as such.
Cut-oﬀ values for RA measurement were established
for the entire study population (groups 1 and 2), which
resulted in a better sensitivity and speciﬁcity than the
current clinical criteria for DXA reimbursement in
Switzerland (Tables 4, 5).
Discussion
The aim of our study was to validate a new case-ﬁnding
strategy for osteoporosis applicable to practicing
physicians in their daily routine and to compare it with
today’s DXA reimbursement-driven practice in Swit-
zerland. According to the latter, screening for osteopo-
rosis using DXA is reimbursed by health insurances only
in a restricted number of circumstances, such as clini-
cally evident osteoporosis or overt fracture after a low
velocity trauma Table (1) . Furthermore, according to
the Federal Health Oﬃce, osteoporosis treatment is to
be reimbursed by health insurances only for persons
who fulﬁll the WHO deﬁnition criteria for osteoporosis
(T-score £ –2.5 SD) at the lumbar spine and/or hip
using DXA.
In the present study, three questions were addressed:
(1) What are the sensitivity and speciﬁcity of the current
DXA reimbursement criteria—as proposed by Swiss
health authorities—in detecting osteoporosis at the spine
and/or hip in postmenopausal women? (2) What would
the sensitivity/speciﬁcity proﬁle of phalangeal RA be in
Fig. 1 Study design
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this very same population? (3) Would phalangeal RA
allow for preselection of postmenopausal women with
low bone mass who do not fulﬁll current DXA reim-
bursement criteria (although exhibiting well-established
risk factors), and if so, what would the speciﬁcity and
sensitivity of this approach be, as compared with the sole
use of general risk factors for osteoporosis?
As documented by the signiﬁcantly larger AUC
achieved by adding RA to the risk factors and age and
anthropometric parameters (height, weight), RA al-
lowed for the preselection of postmenopausal women
with low bone mass. There are numerous studies
showing that risk factors are useful in predicting osteo-
porosis when applied to the general population of wo-
men aged 45 years and older [8, 14, 15]. In those studies,
speciﬁcity ranged between 40 and 60% at a sensitivity
level of 90%, but has been reported to be as low as 20%
in older women [8]. Furthermore, in perimenopausal
women, anthropometric and lifestyle risk factors have
been shown to explain only 19 to 25% of the variability
of BMD at the central skeletal measurement sites [13].
These ﬁndings are consistent with what we found among
our postmenopausal women at a mean age of 61 years:
the combination of age and anthropometric parameters
(height, weight) and risk factors discriminated less
powerfully between women with and without osteopo-
rosis than equations that included RA measure-
ment—even taken alone—as shown by the signiﬁcantly
larger AUC achieved when incorporating RA.
There is no evidence in the literature to date that anti-
osteoporotic treatment reduces fracture risk in patients
treated solely on the basis of risk factors. In fact, the
opposite has been suggested by a recent hip fracture
endpoint study in which risedronate failed to show any
signiﬁcant eﬀect in elderly women selected on the basis
of their risk proﬁle for hip fracture, while hip fracture
incidence was signiﬁcantly reduced in women included
on the basis of a low BMD value at their femoral neck
[31]. Therefore, the presence of risk factors alone has to
Fig. 2 Receiver operating characteristic (ROC) testing the sensi-
tivity and the speciﬁcity of risk factors and RA, alone and
combined. A Group 1 (women with reimbursed DXA indication),
B Group 2 (women without reimbursed DXA indication)
Table 3 Areas under the ROC curves by DXA reimbursement groups
Women with reimbursed DXA indication
(group 1)
Women without reimbursed DXA
indication (group 2)
Area under
the ROC curve
95% CI P value Area under
the ROC curve
95% CI P value
Model 1: age, height, weight 0.709 0.632–0.786 0.702 0.62–0.79
Model 2: age, height,
weight + risk factors*
0.715 0.639–0.790 P =0.72 a 0.707 0.62–0.80 P =0.63 a
Model 3: RA alone 0.781 0.717–0.845 P =0.12 a 0.805 0.72–0.89 P =0.04 a
Model 4: RA + age, height,
weight
0.823 0.764–0.881 P =0.0008 a
P =0.04 b
0.824 0.75–0.90 P =0.004 a
P =0.25 b
Model 5: RA + age, height,
weight + risk factors*
0.830 0.773–0.887 P =0.0004 a
P =0.02 b
0.842 0.77–0.91 P =0.001 a
P =0.08 b
aSigniﬁcance level when compared to model 1; bsigniﬁcance level when compared to model 3. *Risk factors: fracture following a low
velocity trauma, clinically evident osteoporosis (including height loss), history of hypogonadism, gastrointestinal disease, long-term
treatment with glucocorticosteroids, primary hyperparathyroidism, history of hysterectomy or ovariectomy, low dietary calcium intake,
positive family history of osteoporosis, nicotine abuse (>10 cigarettes/day), substitution with thyroidal hormones
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be considered as insuﬃcient to start osteoporosis ther-
apy. Furthermore, although the BMD of any skeletal
site may be useful in estimating an individual’s overall
risk of fracture [32], BMD at the lumbar spine and/or
hip remains the key to decision making for treatment
initiation against osteoporosis, as documented by the
inclusion criteria in virtually all major recent fracture
endpoint studies with risedronate [31, 33, 34], alendro-
nate [35, 36, 37, 38], calcitonin [39], raloxifene [40, 41]
and teriparatide [42, 43].
As proposed in the present study, risk questionnaires
and peripheral BMD measurement devices may not only
be used to estimate a person’s fracture risk, but may also
serve as case-ﬁnding tools to preselect those patients
most likely to have low BMD at the key sites of the spine
and hip, in whom the decision whether to treat or not
can be made after the diagnosis of osteoporosis has been
established or ruled out by subsequent hip and/or spine
DXA measurement.
For the present study, we chose RA as part of the
case-ﬁnding strategy for osteoporotic patients for three
main reasons. First, the phalangeal measurement site is
easily accessible and there is widespread access to con-
ventional X-ray devices among Swiss practicing physi-
cians. Second, RA has been shown previously to predict
low bone mass at the spine and the hip [21, 25] and to be
predictive for vertebral deformities [22], non-vertebral,
vertebral and overall fracture risk [23] as well as hip
fracture risk [24]. Third, our prior experience with RA
showed that the use of phalangeal X-ray as a ﬁrst-line
risk stratiﬁcation tool followed by DXA only in those
patients with a measured RA value below a selected
threshold could potentially be cost eﬃcient when com-
pared to an approach using DXA in all postmenopausal
women, i.e., not limited to those women with risk factors
for osteoporosis [25].
In the present study, the participating physicians se-
lected women with one or several risk factors for oste-
oporosis, i.e., women in whom they had a clinical
suspicion of osteoporosis. The large majority of women
with a reimbursed DXA indication (group 1) had
anamnestic fractures and/or documented height loss. In
these women, age, weight and RA were signiﬁcant pre-
dictors of low BMD at the spine and/or hip. An
Table 5 Sensitivity and speciﬁcity of current DXA reimbursement criteria in Switzerland (all women, with or without reimbursed DXA
indication)
Test Osteoporosisa,
n =109
No osteoporosisb,
n =273
Positive tests
(%, 95% CI)
Sensitivity
(%, 95% CI)
Speciﬁcity
(%, 95% CI)
Presence of reimbursed DXA indication Yes 74 116 48.5 67.9 57.5
No 35 157 (43.4–53.5) (58.2–76.3) (51.4–63.4)
aT-score £ )2.5 SD at spine and/or hip, bT-score >)2.5 SD at spine and hip
Table 6 Sensitivity and speciﬁcity of the RA cut-oﬀ value 95 AU for the pooled patient population (all women, with or without
reimbursed DXA indication)
RA cut-oﬀ
(arbitrary units, AU)
Osteoporosisa,
n =109
No osteoporosisb,
n =273
Positive tests
(%, 95% CI)
Sensitivity
(%, 95% CI)
Speciﬁcity
(%, 95% CI)
<95 AU Yes 104 158 66.9 95.4 42.2
No 5 115 (61.9–71.5) (89.6–98.5) (36.2–48.2)
aT-score £ )2.5 SD at spine and/or hip, bT-score >)2.5 SD at spine and hip
Table 4 RA cut-oﬀ values with related sensitivity and speciﬁcity for women without reimbursed DXA indication (group 2)
RA cut-oﬀ
(arbitrary units, AU)
Osteoporosisa,
n =35
No osteoporosisb,
n =157
Positive tests
(%, 95% CI)
Sensitivity
(%, 95% CI)
Speciﬁcity
(%, 95% CI)
<100 AU Yes 33 107 72.9 94.3 31.8
No 2 50 (66.0 )79.1) (80.8 )99.3) (24.6–39.7)
<95 AU Yes 32 85 60.9 91.4 45.9
No 3 72 (53.7–67.9) (76.9–98.2) (37.9–54.0)
<90 AU Yes 30 65 49.5 85.7 54.6
No 5 92 (42.2–56.8) (69.7–95.2) (50.5–66.4)
<87.5 AU Yes 28 51 41.1 80.0 67.5
No 7 106 (34.1–48.5) (63.0–91.6) (59.6–74.8)
<85 AU Yes 23 43 34.4 65.7 72.6
No 12 114 (27.7–41.6) (47.8–80.9) (64.9–79.4)
aT-score £ )2.5 SD at spine and/or hip, bT-score >)2.5 SD at spine and hip
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unexpected ﬁnding was that women on long-term
treatment with glucocorticosteroids had normal BMD
more frequently than osteoporosis. One possible expla-
nation could be the high awareness and anxiety related
to the iatrogenic side eﬀects of glucocorticosteroids on
bone, leading the participating physicians to include
women with low dose or inhaled glucocorticosteroids in
the study. In the group of women without reimbursed
DXA indications (group 2), age, height, weight and RA
were signiﬁcant predictors of low BMD at the spine and/
or the hip. In this group, RA led to a signiﬁcantly larger
AUC than age, height and weight combined, while the
addition of other risk factors to the logistic regression
model did not improve the AUC further. The sensitivity
and speciﬁcity results in group 2 were less favorable to
RA than the results published earlier in a representative
sample of postmenopausal women [25], where at a sen-
sitivity level of 90% the speciﬁcity of RA to detect
osteoporosis was 67%. This result was expected, as
those women with the highest fracture risk (i.e., those
with previous fracture and/or height loss) were per def-
inition excluded from group 2.
Concerning the sensitivity and speciﬁcity of the cur-
rently accepted criteria for DXA reimbursement, the
present study clearly demonstrates that adherence to
these criteria leads to signiﬁcant under-diagnosing of the
disease. Restricting DXA reimbursement and thereby
DXA measurements at the spine and the hip to women
who fulﬁll one of these criteria leads to the correct
identiﬁcation of only 68% (74/109) of the total of oste-
oporotic patients in this population, while 32% (35/109)
remain unidentiﬁed and therefore untreated—in the
worst case until a ﬁrst fracture occurs (Table 5). In the
patient population participating in this study (patients
with generally accepted risk factors for osteoporosis)
and if following the DXA reimbursement rules, the
practicing physicians would only have addressed 50% of
their postmenopausal women at risk for DXA mea-
surement and thereby would have missed 30% of the
cases with underlying of osteoporosis.
Alternatively, measuring phalangeal RA systemati-
cally in all postmenopausal women with clinical suspi-
cion of osteoporosis, whether or not they match with the
DXA reimbursement criteria, a cut-oﬀ value can be set
at a chosen level that meets the sensitivity expectations
of a medical screening test. For example, choosing a cut-
oﬀ value of 95 AU as an indication for a DXA would
allow to correctly identify 95% (104/109) of all women
with osteoporosis at the spine and/or the hip, while
avoiding DXA measurements in 33% of all women
(Table 6). On the other hand, choosing a sensitivity
similar to that achieved by the current reimbursement
criteria, i.e., around 65%, 56% of women would not
undergo subsequent DXA measurement. Theoretically
and using this approach, a cost neutral price of RA
could be calculated as a percentage of the cost of DXA,
at which the proposed two-step case-ﬁnding approach
would be cost-eﬀective, while identifying more patients
with osteoporosis. A more practical approach would be
to simply add one new criterion for DXA reimburse-
ment, i.e., a phalangeal RA value below a certain cut-oﬀ
in women who do not otherwise qualify for reimbursed
DXA, in line with the women in group 2 of the present
study. Assuming, e.g., a cut-oﬀ value of 95 AU in that
group, this strategy would have a sensitivity of 91.4%,
an acceptable speciﬁcity of 45.9% and only three women
with osteoporosis would be missed (Table 4). This
strategy would increase the percentage of (correctly)
identiﬁed patients with osteoporosis from 68% (74/109)
to 97% (106/109) compared with the current strategy
proposed by the health care authorities (i.e., to measure
only women with reimbursement criteria). Compared
with a broad screening usage of DXA (meaning that all
women in group 2 would have DXA measurements,
too), this strategy would avoid DXA measurements in
39.1% of the women from that group. In earlier studies,
the pre-identiﬁcation of patients with low bone mass
with ultrasound or peripheral DXA bone measurements
has been shown to have good sensitivity and speciﬁcity
in patients with a mean age of 60 to 65 years [18, 19, 44,
45, 46]. In contrast, the same methods applied to peri-
menopausal women aged 45 to 55 years showed poor
speciﬁcity if sensitivity was preserved [47]. In the present
study, the women in group 1 (mean age of 70.2 years
and 39% of the women with osteoporosis) were younger
than the women in group 2 (mean age 64.9 years and
18% of the women with osteoporosis). Whether the re-
sults observed for these patients with risk factors in these
age groups can be generalized to younger patients, i.e.,
to perimenopausal women, could not be answered by
this study.
Apart from their general signiﬁcance for the elabo-
ration of optimum case-ﬁnding strategies for osteopo-
rosis, these results are of special interest for patients not
living near an osteoporosis center, since the above ﬁg-
ures (33 and 39.1%, respectively) of DXA measurements
avoided represent the percentages of women for whom a
visit to the osteoporosis center can be avoided without
compromising on diagnostic quality, as RA can be done
in the nearby physician’s practice.
Conclusion
In conclusion, if the results observed in the present study
could be generalized to women for whom primary care
physicians are considering the possibility of underlying
osteoporosis, RA would be a valid preselection tool for
women with risk factors but who do not meet the current
eligibility criteria forDXAreimbursement in Switzerland.
We therefore propose that detrimental RA values should
be added to the list of reimbursed conditions for DXA
measurement. Patients with clinically evident osteoporo-
sis, fractures following a low velocity trauma, long-term
treatment with glucocorticosteroids, hypogonadism,
gastrointestinal diseases (malabsorption, Crohn’s disease
and hemorrhagic colitis) or primary hyperparathyroidism
should continue to directly undergo aDXAmeasurement
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to avoid incremental costs. To validate the bestRA cut-oﬀ
value to choose, further investigations using a prospective
study design are necessary.
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